National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Kalydeco® is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.

 

Rapid Review

Commenced Completed Outcome
19/11/2015 18/12/2015 Full Pharmaoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
18/03/2016  12/10/2016 Reimbursement Not Recommended at the Submitted Price

Summary

The HSE has approved reimbursement following confidential price negotiations.